Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001057 · ClinicalTrials.gov registry record · Phase 2
The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 7
- Study locations
NCT00001057 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 105 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT00001057, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 7
- Study locations
Study Summary
To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to 550 cells/mm3. Recent studies have shown that during the asymptomatic phase (clinical latency) of HIV infection, there is an extraordinarily large number of infected CD4+ lymphocytes and macrophages throughout the lymphoid system, both in latent and productive states. These findings support the belief that early intervention therapy with reverse transcriptase inhibitors could prolong the clinical latency period.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Didanosine
Study Locations (7)
Minnesota
- Hennepin County Med Clinic - Minneapolis
- Univ of Minnesota - Minneapolis
- St Paul Ramsey Med Ctr - Saint Paul
Nebraska
- Univ of Nebraska Med Ctr - Omaha
Ohio
- Case Western Reserve Univ - Cleveland
Pennsylvania
- Thomas Jefferson Univ Hosp - Philadelphia
Texas
- Univ of Texas Galveston - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Est. Completion | 1995-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001057
The ClinicalTrials.gov registry entry for NCT00001057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00001057 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Minnesota, Nebraska, Ohio.
Frequently Asked Questions
What is clinical trial NCT00001057 about?
NCT00001057 is a clinical study titled "The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients". To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to 550 cells/mm3. Recent studies have shown that during the asymptomatic ph...
What is the current status of trial NCT00001057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. Estimated completion is 1995-05.
What conditions does trial NCT00001057 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00001057?
The interventions under investigation include: Zidovudine (DRUG), Didanosine (DRUG).
Who is sponsoring clinical trial NCT00001057?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001057 being conducted?
This trial has 7 study locations across Minnesota, Nebraska, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.